Study wrapper · #937
Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.
Zhang Y, Zhang C, Gong X, et al. European journal of medical research. 2026.
DOI: 10.1186/s40001-026-03933-9PubMed: 41582189
Editor's note
This network meta-analysis pools twelve randomized trials and reports a consistent heart-rate increase across the GLP-1 agonist class. The signal is a well-documented pharmacological effect rather than a new finding, and the analysis is limited by heterogeneity across the included trials. Useful context for the cardiovascular profile of these agents.
Plain-language abstract
A meta-analysis of randomized trials found that GLP-1 receptor agonists, including semaglutide, tirzepatide, and retatrutide, were associated with modest increases in resting heart rate in people with overweight or obesity who did not have diabetes.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026